Internal Medicine, Medical Oncology · Lexington, KY
NPI
1629280656
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1720 Nicholasville Rd, Suite 701
Lexington, KY, 40503
Phone (859) 276-0414
Groups this clinician bills Medicare through
Medicare paid, 2024
$88K
1,008 services
Medicare patients, 2024
340
Average age 75
Drug cost, 2024
$8.7M
2,462 prescriptions
Company payments, 2025
$3,537
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Arvinda Padmanabhan was code 99214 (office e&m - established), 581 times for 204 patients. In total Arvinda Padmanabhan billed 1,008 services in 17 codes, and Medicare paid $88K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-12-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 581 | 204 | $89.56 | $52K |
| 99213 Office E&M - Established | Office | 120 | 99 | $60.47 | $7,257 |
| 99215 Office E&M - Established | Office | 59 | 35 | $136.10 | $8,030 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 44 | 37 | $12.88 | $567 |
| 99204 Office E&M - New | Office | 44 | 44 | $120.66 | $5,309 |
| 99222 Hospital E&M - Initial | Facility | 36 | 30 | $102.33 | $3,684 |
| 99232 Hospital E&M - Subsequent | Facility | 32 | 12 | $61.88 | $1,980 |
| 99205 Office E&M - New | Office | 30 | 30 | $168.06 | $5,042 |
| 99231 Hospital E&M - Subsequent | Facility | 22 | 14 | $38.86 | $855 |
| 99203 Office E&M - New | Office | 15 | 15 | $86.32 | $1,295 |
By year: 2022 $82K for 974 services; 2023 $83K for 931 services; 2024 $88K for 1,008 services.
Medicare prescription drug claims, 2024
In 2024, the drug Arvinda Padmanabhan prescribed most often to Medicare patients was Ondansetron Hcl, with 180 prescriptions and refills. In total Arvinda Padmanabhan wrote 2,462 Medicare prescriptions that cost $8.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ondansetron Hcl Generic | 180 | 184 | 90 | $14K |
| Dexamethasone Generic | 106 | 117 | 28 | $1,717 |
| Acyclovir Generic | 83 | 133 | 23 | $1,256 |
| Anastrozole Generic | 80 | 206 | 32 | $1,348 |
| Erleada Apalutamide | 74 | 74 | Under 11 | $1.1M |
| Eliquis Apixaban | 73 | 96 | 22 | $55K |
| Brukinsa Zanubrutinib | 63 | 63 | Under 11 | $754K |
| Tamoxifen Citrate Generic | 62 | 155 | 19 | $2,132 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 61 | 64 | 14 | $132 |
| Lenalidomide Generic | 57 | 57 | Under 11 | $569K |
| Olanzapine Generic | 51 | 57 | 24 | $228 |
| Orgovyx Relugolix | 51 | 51 | Under 11 | $149K |
| Revlimid Lenalidomide | 50 | 50 | Under 11 | $608K |
| Prochlorperazine Maleate Generic | 49 | 49 | 16 | $924 |
| Venclexta Venetoclax | 43 | 43 | Under 11 | $573K |
Brand drugs: - claims; generic drugs: 1,758 claims; opioid claims: 160.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Arvinda Padmanabhan $3,537 ($3,537 in general payments such as food, travel and fees) from 33 companies. The largest payer was Merck Sharp & Dohme LLC with $1,473.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 18 | $1,473 |
| Pfizer Inc. PFE | 17 | $272 |
| Janssen Biotech, Inc. JNJ | 12 | $209 |
| Astellas Pharma US Inc 4503.T | 11 | $161 |
| Abbvie Inc. ABBV | 5 | $120 |
| Seagen Inc. PFE | 1 | $92.99 |
| Daiichi Sankyo Inc. 4568.T | 4 | $87.95 |
| Eisai Inc. 4523.T | 4 | $85.84 |
| Gilead Sciences, Inc. GILD | 4 | $82.04 |
| Genentech USA, Inc. ROG.SW | 4 | $76.89 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.